Journal
PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 28, Issue 9, Pages 835-837Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0b013e3181a165e4
Keywords
antibodies; bronchiolitis; monoclonal; antiviral agents clinical trial; motavizumab; pediatric; respiratory syncytial virus; viral load
Categories
Ask authors/readers for more resources
Previously healthy children hospitalized with respiratory syncytial virus (RSV) received motavizumab (3, 15, or 30 mg/kg intravenously), an RSV-specific monoclonal antibody, or placebo. Safety, tolerability, motavizumab concentrations, and immunogenicity were assessed. Cultivatable RSV in the upper respiratory tract was significantly reduced with motavizumab compared with placebo day 1 post-treatment. No adverse events were considered motavizumab-related by site investigators.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available